Please login to the form below
kidney disease
This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.
GSK’s says depot HIV injection works over three years
a potential treatment for anaemia associated with chronic kidney disease.
Latest news
-
NICE says no to AZ and Vifor’s rival hyperkalaemia drugs
Most common in patients with poor kidney function, heart failure or liver disease, hyperkalemia can be fatal, and patients have had few options for treatment until now. ... The companies argue that this exposes patients to cardiovascular disease risk,
-
Artificial intelligence in healthcare
What are the benefits for pharma? There seem to be almost endless ways artificial intelligence (AI) could transform healthcare, such as preventing disease and improving diagnoses and treatment, but for pharma ... the Royal Free NHS Foundation Trust for a
-
Novo Nordisk and Evotec inks drug development deal
molecule therapies to treat the disease. ... Obesity is another area that’s of interest to the recently formed partnership, along with non-alcoholic steatohepatitis (NASH), cardiovascular disease and diabetic kidney disease.
-
Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka
Otsuka gains European nod for Jinarc extension. The European Commission has approved a label extension for Jinarc (tolvaptan) to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease ... Jinarc is the only drug treatment
-
Amgen’s R&D chief Sean Harper retires to seek biotech post
Bradway said two new products – Aimovig (erenumab) for migraine and Sensipar follow-up Parsabiv (etelcalcetide) for chronic kidney disease – had started well, and the quarter was also marked by the launch
More from news
Approximately 16 fully matching, plus 119 partially matching documents found.
Latest Intelligence
-
China: AstraZeneca’s new engine for growth and innovation
FibroGen in China for patients with anaemia in chronic kidney disease. ... AstraZeneca’s goal is to realise complete disease management, covering prevention, screening, diagnosis, treatment and follow- up.
-
The invisible army
Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.
-
Deal Watch December 2016
1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... inflammatory bowel disease and multiple sclerosis.
-
Business as usual
He also cautioned delegates over 'dual use', describing a situation where ferric citrate was promoted at a kidney disease symposium. ... It was described as being FDA-approved - which it is, but not for the treatment of kidney disease.
-
Deal Watch February 2016
The company is developing oral biologics that deliver disease specific amino acid compositions to restore balance in disease pathways in indications such as muscle, neurodegenerative and liver diseases. ... licence. 105. †† Genexine/ Shanghai Chemo
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
Sanifit appoints Alexander Gold chief medical officer
Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Lighthouse Medical Communications US makes the list of finalists for the 2018 PM360 Trailblalzer Awards
This exciting news is a true testament to the American Kidney Fund’s commitment to improving the lives of patients with chronic kidney disease. ACT on Anemia was one of a ... ACT on Anemia - Anemia in Chronic Kidney Disease, is a multi-channel
-
Making good practice common practice in rare disease
However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Associate Director
-
£75, 000-90, 000
-
Account Manager
-
Negotiable
- Account Manager- Healthcare Advertising
-
Negotiable
-
Business Director
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Senior Account Manager
-
Competitive Salary Offered
- Business Development Director – Health Education
-
excellent commission
- Principal Health Economist - North-West
-
Negotiable
- Account Manager / Senior Account Manager
-
35, 000-40, 000
Subscribe to our email news alerts
- Fishawack acquires Blue Latitude Health
- FDA clears Sandoz and Pear’s Opioid Use Disorder app
- As May delays, industry warns again of ‘no-deal’ Brexit
- Clark Health Communications and Egg digital announce new collaboration
- Axovant drops last ‘legacy’ drug to focus on gene therapies
- Healthcare excellence celebrated at 2018 HSJ Awards
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
